Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Research analysts at HC Wainwright raised their FY2026 earnings per share estimates for Monopar Therapeutics in a report released on Thursday, November 12th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings of ($2.80) per share for the year, up from their prior forecast of ($3.07). HC Wainwright has a "Buy" rating on the stock. The consensus estimate for Monopar Therapeutics' current full-year earnings is ($2.96) per share. HC Wainwright also issued estimates for Monopar Therapeutics' Q4 2026 earnings at ($0.99) EPS, FY2027 earnings at ($4.32) EPS, FY2028 earnings at ($0.13) EPS, FY2029 earnings at $5.13 EPS and FY2030 earnings at $7.93 EPS.
Several other research analysts have also weighed in on MNPR. Zacks Research lowered shares of Monopar Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 13th. Cantor Fitzgerald raised shares of Monopar Therapeutics from a "neutral" rating to an "overweight" rating and set a $119.00 price target on the stock in a research note on Thursday. BTIG Research reissued a "buy" rating on shares of Monopar Therapeutics in a research note on Thursday. Wall Street Zen cut shares of Monopar Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, October 10th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Monopar Therapeutics in a research report on Thursday, October 15th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Monopar Therapeutics has an average rating of "Moderate Buy" and an average target price of $122.75.
Check Out Our Latest Stock Analysis on Monopar Therapeutics
Monopar Therapeutics Stock Performance
Shares of MNPR opened at $72.00 on Monday. The firm has a market cap of $483.26 million, a P/E ratio of -29.88 and a beta of 1.62. Monopar Therapeutics has a 12-month low of $50.07 and a 12-month high of $124.82. The company's 50-day moving average price is $82.59 and its 200 day moving average price is $77.41.
Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.72) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.72).
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in the business. Meeder Asset Management Inc. increased its stake in Monopar Therapeutics by 18.9% during the 3rd quarter. Meeder Asset Management Inc. now owns 1,651 shares of the company's stock worth $132,000 after buying an additional 262 shares during the period. The Manufacturers Life Insurance Company acquired a new stake in Monopar Therapeutics during the 1st quarter worth approximately $250,000. Sei Investments Co. lifted its holdings in Monopar Therapeutics by 9.5% during the 1st quarter. Sei Investments Co. now owns 7,582 shares of the company's stock worth $415,000 after buying an additional 656 shares in the last quarter. Bank of America Corp DE boosted its position in Monopar Therapeutics by 838.2% in the 1st quarter. Bank of America Corp DE now owns 59,699 shares of the company's stock valued at $3,271,000 after buying an additional 53,336 shares during the period. Finally, Walleye Capital LLC purchased a new position in Monopar Therapeutics in the 1st quarter valued at approximately $3,458,000. Hedge funds and other institutional investors own 1.83% of the company's stock.
Insider Transactions at Monopar Therapeutics
In other Monopar Therapeutics news, CEO Chandler Robinson sold 29,056 shares of Monopar Therapeutics stock in a transaction dated Thursday, September 24th. The stock was sold at an average price of $88.00, for a total value of $2,556,928.00. Following the completion of the transaction, the chief executive officer directly owned 99,267 shares of the company's stock, valued at $8,735,496. The trade was a 22.64% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kim R. Tsuchimoto sold 4,090 shares of the business's stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $111.39, for a total transaction of $455,585.10. Following the sale, the director owned 7,396 shares in the company, valued at $823,840.44. This trade represents a 35.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 51,920 shares of company stock worth $4,527,913 in the last 90 days. Insiders own 9.70% of the company's stock.
Latest Monopar Therapeutics News
Here's some of the latest news about MNPR:
- Positive Sentiment: Cantor Fitzgerald upgraded MNPR from “Neutral” to “Overweight” and set a $119 price target, implying substantial upside from the cited $72 share price. Cantor Fitzgerald rating article
- Positive Sentiment: Monopar reported third-quarter 2026 EPS of a $0.72 loss, better than analysts’ consensus estimate of a $0.82 loss. The company also released quarterly results and business updates. Third-quarter results and business updates
- Neutral Sentiment: HC Wainwright maintained its “Buy” rating and issued 2027 quarterly EPS estimates ranging from a $0.91 to a $1.19 loss per share. The projections indicate continued expected losses, but no change in rating was reported.
About Monopar Therapeutics
(
Get Free Report)
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its pipeline includes radiopharmaceutical candidates designed to target the urokinase plasminogen activator receptor (uPAR), a protein found at elevated levels in some cancers. The company is developing MNPR-101-Zr as an imaging agent to identify uPAR-expressing tumors and MNPR-101-Lu as a potential targeted radiation therapy. These candidates are investigational and are not approved for commercial use.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Monopar Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Monopar Therapeutics wasn't on the list.
While Monopar Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.